Cisplatin-based therapy results in a cumulative anemia that is disproportionate to the effects on other blood cells. The severity of this treatment-induced anemia and the resultant transfusion requirement in cancer patients correlate with cisplatin-induced renal tubular dysfunction. Observed/expected serum erythropoietin (EPO) ratios decline with progressive cisplatin therapy and are proportionate to the degree of renal dysfunction. Recovery from anemia and of observed/expected serum EPO ratios in patients occurs after cessation of cisplatin therapy, along with restoration of renal tubular function. Creatinine clearance, however, remains permanently depressed. Cisplatin-treated rats develop progressive renal dysfunction and anemia that persists for many weeks, without effects on white blood cell counts. The anemia is also associated with a lack of expected EPO and reticulocyte response. With EPO administration, cisplatin-treated rats exhibit a greater reticulocyte response and hematocrit increment then non-cisplatin-treated rats given EPO, indicating minimal erythroid precursor cell damage from cisplatin. These results indicate the primary etiology of cisplatin-associated anemia is a transient, but persisting EPO deficiency state resulting from cisplatin-induced renal tubular damage, which can be prevented or treated by hormone (EPO) replacement. (J. Clin. Invest. 1995. 95:1650-1659
Introduction
The major source of erythropoietin (EPO)' in the adult is the kidney, with evidence for production by peritubular interstitial cells ( 1, 2) although some studies argue for a renal tubular cell origin (3) . The anemia of chronic and acute renal failure is largely the result of an EPO deficiency due to decreased EPO production from the diseased kidney (4, 5) . Administration of EPO promptly corrects the anemia associated with renal failure in the majority of patients (6, 7) .
Cisplatin is a widely used metal-based anticancer drug that causes early and progressive renal tubular dysfunction and subsequent glomerular drop out. Chronic administration of cisplatin in animals (8) (9) (10) and in cancer patients (11, 12) has been reported to cause progressive anemia at moderate levels of azotemia that appears disproportionate to the effects on white blood cells. The occurrence of a predominant deficiency in erythrocyte production along with renal toxicity suggests that this drugassociated anemia might result in part from deficient renal production of EPO due to cisplatin-induced renal toxicity. The often complex nature of anemia in cancer patients, frequent administration of myelotoxic drugs along with cisplatin, frequent use of red cell transfusions, infrequency with which anemia is reported, and incomplete characterization of anemia in clinical cancer trials have prompted us to look at this issue more carefully.
We have studied a homogeneous and well-defined group of cancer patients receiving prolonged cisplatin-based therapy. This study attempts to describe carefully the hematologic characteristics and degree of cisplatin-associated anemia and contrasts it with other associated cytopenias. Cisplatin-associated anemia is correlated with markers of tubular and overall renal damage. Finally, this study evaluates the resulting serum EPO response to the anemia. Because this group of patients received a general marrow toxin (doxorubicin) as well as cisplatin, we also studied purely cisplatin-induced renal toxicity and anemia in rats. These studies define the endogenous EPO response to pure cisplatin-induced anemia and the response of this anemia to recombinant human EPO.
Methods

Clinical studies
Patients. All patients signed informed consent for study participation. The study protocol was approved by the Institutional Review Board. 54 patients were initially enrolled. Seven of these patients were subsequently excluded from study (see exclusion criteria). The 47 remaining patients are the basis of this report. These 47 patients had either ovarian (n = 28) or bladder (n = 19) cancer and were studied over a span of 7 yr in the Clinical Research Center at the University of Minnesota. These patients had advanced stage ovarian or bladder tumors as follows:
ovarian cancer: 1 stage IC with peritoneal spill, 18 stage III, 9 stage IV patients; bladder cancer: 3 stage C, 5 stage DI, 11 stage D2 patients.
The median age was 60.0±1.5 yr (range 45-88 yr) with a male/female ratio of 1:2.9. 87% of patients had surgical resection of their ovarian disease or primary bladder cancer on average 42 d before study entry. Three patients had received prior radiation therapy (1 mo, 16 mo, and 12 yr before study), two had received prior non-cisplatin chemotherapy (oral melphalan and tamoxifen, intravenous cyclophosphamide), and one patient had received both prior radiation therapy (2 yr before study) and local chemotherapy (intravesicular thiotepa).
Chemotherapy protocol. hemoglobin is half-saturated by cooxymetry) were determined in a subset of five patients. Serum EPO levels were measured by commercial assays using a solid-phase enzyme immunoassay with a mAb to recombinant human-EPO (JCL Clinical Research Corp., Knoxville, TN). The normal range for EPO values was 7-38 mU/ml. Using the log relationship between serum EPO and hematocrit from large groups with normal hematocrits and subjects with uncomplicated anemia, an expected log EPO value was calculated for each patient's concurrent hematocrit. The following formula was used: log EPO = -0.098 (hematocrit) + 5.57. The appropriateness of the EPO response was estimated by calculating the ratio of the observed/expected (O/E) serum EPO values multiplied by 100 for each hematocrit. Red cell transfusions were routinely given just before a monthly chemotherapy cycle, when the hematocrit fell to < 26-28%. The cumulative number of red cell transfusions was recorded for each patient throughout therapy.
Exclusion criteria. Seven patients were excluded from the study for the following reasons to eliminate well-documented additional causes for anemia or alteration in EPO levels due to reasons other than malignancy: iron deficiency (n = 3) and significant inflammatory or metastatic hepatic disease (n = 3) (> 30% tumor involvement or liver enzymes and baseline ferritin levels two to three times normal). Hepatic disease itself has been reported to alter EPO production (13) . One patient was excluded for completion of less than four courses secondary to early tumor progression.
Rat studies Cisplatin treatment. Procedures for animals followed approved National Institutes of Health guidelines with local Institutional Animal Care Committee review. Female Fischer 344 rats given repeated cisplatin were studied as a model of cisplatin renal damage and anemia, which parallels the renal damage seen with chronic cisplatin administration in humans (14, 15) . Two separate studies were conducted using 20 rats (n = 10 per treatment group), at age 15 wk in study I, and 32 rats (n = 16 per treatment group), at age 9 wk in study II. Equal numbers of rats were treated twice weekly with 2 mg/kg cisplatin dissolved in mannitolcontaining saline (Bristol Meyers, Princeton, NJ) or saline alone by the intraperitoneal route. Rats received a total of eight injections of cisplatin or saline over 25 (Table I ). The onset of this hemoglobin decline was not delayed but was seen after the first course of therapy, with continued progression with further therapy. An average hemoglobin decline of 0.22 g/dl per course was observed when considering only values before the first red cell transfusion (n = 253, r = 0.38, P < 0.001). This rate of hemoglobin decline underestimates the true rate of hemoglobin decline because of the necessity to administer red cell transfusions. Without red cell transfusion, the true rate of hemoglobin decline would obviously be much steeper. The lowest hemoglobin value recorded 4 wk after therapy was 5.9 g/dl. In contrast to this progressive anemia, total white blood cell and platelet counts showed only a slight decline within the normal range. Additionally, the greatest decline in blood leukocytes occurred after the first few courses and was much less prominent later in therapy.
Characteristics of treatment-induced anemia Reticulocyte response and transfusions. Before red cell transfusions, corrected reticulocytes failed to rise with successive chemotherapy courses despite progressive anemia (Table I ). This Nutritional studies. Initial values and those measured upon study completion for serum B12 (496±87 vs 525+±53 pg/ml, respectively) and red cell folate (337±19 vs 471+29 ng/ml) did not differ and remained within the normal limit. Despite the lack of a reticulocytosis, B12, or folate deficiency, therapyinduced anemia was associated with a progressive increase within the normal range of mean red cell volume (86.6±0.8 to 95.2±0.6 fl, P < 0.001) and mean cell hemoglobin concentration (33.7±0.1 to 34.2+0.1 g/dl, P = 0.004) tabulated before intervention with any red cell transfusions. The red cell distribution width of erythrocyte size before any transfusion remained unchanged during treatment (15.0+0.4 vs 16.3±0.3, P = NS).
Iron studies. Serum iron (58+3.9 to 105.6±5.7 ug/dl, P < 0.001) and percent saturation (23.6±1.7 to 38.8±2.4%, P < 0.001) both increased progressively within the normal range by the end of treatment. Total iron binding capacity remained unchanged (263±+11 vs 276±8 4g/dl, P = NS). In the absence of any significant hepatic disease or toxicity, serum ferritin levels increased markedly and progressively with therapy (initial 239+43, after two to five courses 472+81, after six to nine courses 731±84 ng/ml, P < 0.001). Ferritin levels correlated well with the total number of red cell transfusions received (n = 132, r = 0.75, P < 0.001).
Oxygen affinity. Hemoglobin oxygen affinity was measured in whole blood samples in a small group of patients during treatment (n = 5) with a range of renal dysfunction CrCl 64-123 (cm3/min per 1.7 m2) and hematocrit values (23-33%). The P50 did not differ between these patients during treatment and normal volunteers (P50: patients 27 .1±2.1 mmHg vs normal 26.8+0.6 mmHg).
Tagged red cell studies. 5tCr-tagged red cell studies were performed in five patients after treatment. These studies confirm the presence of anemia with a decreased in total red cell mass to 18.7±1.5 cm3/kg (normal 22-32 cm3/kg) after more than two courses of treatment. The red cell mass in these patients correlated inversely with the degree of renal toxicity measured by concurrent 24-h CrCl (r = 0.89, P = 0.046). Red cell halflife was measured in four of these same five patients after more than two courses of therapy. Three of these patients had not received red cell transfusions. One patient had received several red cell transfusions and was studied 1 mo after the last transfusion. Red cell half-life values, measured 1 mo after chemotherapy, were diminished by nearly 40% in all four of these patients to 16.5±0.6 d (normal 25-30 d), which correlated with, but did not approach significance, the degree of anemia (r = 0.93, p = 0.068). The measured red cell half-life in the one transfused patient did not differ markedly from the values in the nontransfused patients.
Bone marrow studies. Bone marrow biopsies before therapy (n = 8) were normocellular, with a qualitative decrease in sideroblasts and increased iron stores consistent with the anemia of malignancy. One patient had tumor cells detected in the marrow before therapy. After more than four courses of therapy, bone marrow (n = 23) cellularity was mildly decreased. The myeloid/erythroid ratio remained unchanged in the lower range of 3-4:1. The number of sideroblasts increased to the normal range, and iron stores further increased.
Serum EPO response during cisplatin-based chemotherapy Before therapy, on average, these patients with advanced cancer had a mild anemia (hematocrit 36.7±0.5%, range 28.2-44.6%) without apparent cause other than cancer. In response to this mild anemia, the average serum EPO concentration was 41.1±5.6 mU/ml (normal range 7-38 mU/ml). There was no significant correlation between the log EPO values and concurrent hematocrit ( Fig. 1; r 
Predictors of therapy-induced anemia
Cisplatin-induced renal dysfunction. The degree of therapy-induced anemia correlated with the amount of cisplatin-induced renal damage. This relationship was reflected by a correlation of hematocrit and 24-h CrCl (n = 250, r = 0.35, P = 0.004). Red cell mass measurements in a subset of patients also correlated with 24-h CrCl. Hematocrit correlated more strongly with a measure more relevant to renal tubular function, the serum magnesium level (P = 245, r = 0.44, P < 0.001) (Fig. 2 ).
There was a significant inverse correlation between the amount of renal damage (CrCl) and the number of cumulative red cell transfusions (n = 404, r = 0.49, P < 0.001) (data not shown). Patients receiving > 3 total U of red cells had lower final 24-h CrCl than those receiving < 3 U (P = 0.025). The proportion of patients requiring magnesium supplementation was higher in patients receiving > 5 U (P = 0.072) and > 7 U (P = 0.028) of red cells than those receiving fewer transfusions.
The degree of EPO response to therapy-induced anemia correlated with the amount of cisplatin-induced renal damage. This relationship was reflected by a correlation between the O/ (Fig. 4) . Several days after stopping cisplatin treatment, renal dysfunction reached a plateau and remained abnormal over the next 25 d of observation. Cisplatin-induced hematologic toxicity. A progressive anemia accompanied this cisplatin-induced renal damage. Hematocrits gradually fell during cisplatin administration and reached a nadir shortly after the last dose (Fig. 4) . The difference in peripheral hematocrit points between saline-and cisplatintreated rats was 12% in study I (data not shown) and 8.3% in study II (54.9±1.0% vs 46.6±1.1%, P < 0.001). The hematocrits remained depressed over the next 25 d of observation. There was a significant inverse correlation of the hematocrit and serum creatinine in cisplatin-treated rats (n = 48, P < 0.01).
The reticulocyte response varied between saline-and cisplatin-treated rats (Fig. 4) . Saline-treated rats showed a slight rise in blood reticulocyte concentrations over pretreatment values, reflecting the effects of weekly blood sampling, whereas the hematocrit remained unchanged. Cisplatin-treated rats failed to increase their blood reticulocytes both during and following cisplatin administration, despite progressive anemia. Reticulo- 1 ) and at the end of saline or cisplatin treatment (days 22-29) were compared in study II. Plasma EPO levels of cisplatin-treated rats did not differ from those of salinetreated rats or rats evaluated before treatment (Table V) despite the fall in hematocrit in cisplatin-treated rats. This is in contrast to the significant elevation of plasma EPO levels seen in rats rendered anemic by APH, which causes a depression in hematocrit with an appropriately elevated reticulocyte response.
Response to exogenous human recombinant EPO. In study H, administration of subcutaneous recombinant human EPO twice weekly, 6 d after cessation of cisplatin, rapidly increased the hematocrit and blood reticulocytes (Fig. 4) in cisplatin-and saline-treated rats. The final EPO-induced increment in hematocrit was significantly greater in cisplatin-treated rats given EPO than in non-cisplatin-treated rats given EPO (21.8±1.1 vs 13.6±0.8 points, P < 0.001). The EPO-induce increment in blood reticulocytes was also greater in cisplatin-treated rats given EPO (P < 0.05) than in non-cisplatin-treated rats given EPO. EPO treatment did not alter serum creatinine values in cisplatin-or saline-treated rats (Fig. 4) . In study I, subcutaneous EPO was initiated 32 d after completing cisplatin treatments.
Greater hematocrit increments were also seen in previously cisplatin-treated rats than non-cisplatin-treated rats (22 vs 15-point increment, P < 0.001) (data not shown). (24) . The anemia occurs early, is cumulative, is disproportionate to white blood cell changes, and necessitates red cell transfusion in the vast majority of successfully treated cancer patients. Bone marrow cellularity was slightly depressed; however, myeloid/erythroid ratios were preserved. A hypoproliferative anemia could result from drug-induced EPO deficiency and/or direct drug-induced suppression of marrow precursors. We present evidence that cisplatin-associated anemia in cancer patients and in normal rats is associated with inhibition of the endogenous EPO response, which in both cases correlates with cisplatin-induced renal damage. The cisplatin-induced anemia in the rat can be rapidly obviated by EPO. Others have demonstrated that anemia in cancer patients receiving cisplatin-containing chemotherapy can be effectively alleviated by EPO (25) (26) (27) (28) .
Cisplatin has not been associated clinically with significant multilineage marrow toxicity at moderate doses. This granulopoietic sparing effect of cisplatin accounts for much of its success when combined with full doses of myelotoxic drugs. The myelotoxicity of single-agent cisplatin has been manifested by mild leukopenia in a minority of heavily pretreated patients ( 12, 29) or in similar proportions of better performance patients given cisplatin at higher doses (30) . These white cell changes have been transient and not cumulative, unlike the anemia. Cisplatin administration in animals has caused either no myelotoxicity or transient changes in white blood cell numbers and marrow progenitor numbers at high doses (9, 31, 32) . We found that repeated, moderate dose cisplatin administration in rats caused anemia with no persistent effects on white blood cell counts.
The anemia in these cisplatin-treated rats with mild azotemia responded vigorously to EPO administration, generating an erythropoietic response greater than that in non-cisplatin-treated rats given EPO. Matsumoto et al. studied the response of rats to EPO and found it more effective in correcting the anemia induced by cisplatin than the anemia induced by 5-fluorouracil (8) . This is interesting in light of our observations in rats of the apparent dissociation of cisplatin-induced anemia and renal dysfunction from marrow damage. In contrast, 5-fluorouracil causes anemia with elevated EPO levels and direct toxicity to the bone marrow progenitors. Collectively, these findings further support the idea that the anemia associated with repeated cisplatin administration is largely a hormone deficiency (EPO) secondary to damage to renal tubular and/or peritubular tissues that sense hypoxia and/or produce EPO. Most clinical EPO trials in patients receiving cisplatin have not reported serial measures of renal function or cumulative cisplatin doses and have excluded patients when their renal function declined. Therefore, it is not known whether cisplatin-induced anemia in patients with significant drug-induced renal dysfunction responds better to EPO than anemia in chemotherapy patients without cisplatin nephropathy, as it does in rats.
EPO deficiency with cisplatin therapy has been suggested in previous studies to contribute to anemia (10, 12, 33) . The EPO response (percentage of expected EPO level for the hematocrit) in our patients decreased with each course and correlated with the 24-h CrCl and serum magnesium. Plasma EPO concentrations in rats treated with several doses of cisplatin also failed to increase in the face of progressive anemia and moderate renal dysfunction. These results are consistent with the lack of an EPO response seen in rats treated with single-dose cisplatin and correction with EPO administration reported by Matsumoto et al. (8) . Whether the reduction in the EPO response is the result solely of renal dysfunction or whether, in addition, the deficiency in magnesium itself may impair EPO production or release is not known but could be tested in further studies.
Cisplatin chemotherapy in smaller patient series has been reported to cause a delayed, progressive anemia, disproportionate to white cell changes, in over half of patients that then require transfusions (11, 34, 35) . The development of anemia in our patients, however, was not delayed, but was seen immediately after the first course of therapy and progressed with further treatment. An explanation other than just decreased red cell production from EPO deficiency seems necessary to explain these observations, given a normal red cell life span of 120 d. Other contributing factors to this earlier than expected anemia onset might be the diminished red cell half-life seen in the anemia of chronic disease, which has been, in part, attributed to factors outside the red cell based on cross-transfusion studies (36) . In a subset of our patients undergoing cisplatin-based chemotherapy, we demonstrated a 40% decrease in the red cell half-life compared with the values in normal volunteers. EPO itself has an apparent affect on red cell half-life, since disorders associated with a deficiency in EPO have a decrease in red cell half-life, and the administration of recombinant EPO in these disorders increases the red cell half-life (37, 38) . EPO can prolong the survival of CFU-E precursors and proerythroblasts by preventing cell apoptosis (39) , but how this translates to prolonged mature erythrocyte life span is not clear. In our cisplatin-treated cancer patients, shortened red cell half-life due to the malignant process and to the progressive deficiency in EPO and decreased production of red cells from EPO deficiency could all contribute to an early fall in hemoglobin. Doxorubicin given concurrently to these cancer patients would also transiently inhibit red cell production through direct marrow toxicity. Additional direct effects of these drugs on red cell survival through subtle oxidative effects are possible but were not measured. Immune-mediated destruction of red cells reflected by the absence of direct Coomb's positively was not found. Cisplatin in animal models causes an anemia with a delayed appearance of about 2 wk after single (8, 9) or repeated doses (10). Cisplatin anemia in our rats was also delayed and cumulative, and it persisted for more than 4-7 wk after treatment. The model of the cisplatin-treated rat differs from these patients in that rats did not have tumors and doxorubicin was not administered. These differences could alter the rate of fall of hemoglobin by the lack of a tumor effect on red cell half-life and the lack of a marrow effect from doxorubicin. The recognition of an earlier onset of anemia with cisplatin chemotherapy in patients may warrant the earlier intervention with prophylactic administration of EPO to prevent this anemia. The majority of EPO trials in chemotherapy patients receiving cisplatin (25) (26) (27) (28) or noncisplatin (40, 41) chemotherapy have initiated EPO therapy after the appearance of anemia, with improved hematocrits and decreased transfusion rates.
Anemia in our cancer patients was highly associated with the progressive development of cisplatin-induced renal dysfunction, as indicated by 24-h CrCl, but was more strongly correlated with renal tubular damage (fall in serum magnesium). Our transfusion rates correlated with cisplatin-induced renal damage. Rates of red cell transfusions have been reported to be higher in cisplatin-than non-cisplatin-containing chemotherapy (35) . Other studies, however, have failed to find a correlation between cisplatin-induced anemia and renal function (33, 42) . Many of these studies have reported small patient numbers, heterogeneous tumor types, variable chemotherapy regimens, and lower cumulative cisplatin doses. Many cisplatin studies have not followed renal function serially and have not thoroughly characterized anemia before and during chemotherapy. Serum creatinine concentrations have often been used to measure cisplatin-induced renal damage; such measurements poorly reflect kidney damage that is primarily tubular. We have tried to overcome many of these shortcomings in our study. The strongest correlation we found was between the decrement in serum magnesium concentrations and anemia during therapy. This was further supported by the correlation of restoration of serum magnesium levels with the correction of anemia and EPO response in long-term follow-up of patients in the absence of restoration of CrCl values. Cisplatin-associated anemia and blunted EPO response occur at a level of renal glomerular dysfunction, measured by 24-h CrCl, far less severe than that associated with other causes of renal dysfunction. This also indicates that cisplatin may well cause a relatively more specific or targeted non-glomerular cell damage. Amphotericin B is an example of another renal tubular poison that is associated with renal magnesium wasting, anemia, and an inappropriately low EPO response that only gradually resolve after stopping the drug (43) . It can be argued that an even better measure of renal tubular or peritubular cell function than serum magnesium could be a more useful anemia predictor with these types of drugs.
The exact mechanism by which cisplatin-induced renal damage prevents an EPO response to anemia is not known. Cisplatin could conceivably inhibit renal sensing of anemia and/or renal production of EPO. Cisplatin can react with nucleophilic sites in not only DNA, but also RNA and protein. Cisplatin forms complexes with cellular glutathione, which then can directly inhibit protein synthesis (44) . Cisplatin is eliminated by renal excretion and is more highly concentrated in renal tissue, where it demonstrates very prolonged (weeks) tissue retention, than in any other tissue type (45, 46) . Increased tissue deposition of platinum also occurs with repeated administration of cisplatin (47) . Though cisplatin clearly damages renal tubular epithelial cells, as shown by histologic changes and markers of renal tubular cell function, changes in renal interstitial tissues also occur, including edema and fibrosis ( 12, 16) . Cisplatin-induced alterations in renal tubular function (renal tubular magnesium wasting) appear to be slowly reversible; however, changes in CrCl appear to be fixed, as reported here and elsewhere (16, 17) . Therefore, accumulation of cisplatin and/or redistribution of other metals by cisplatin (48) within the tubular or peritubular spaces of the kidney might lead to inhibition of the sensing mechanism for tissue hypoxia or inhibition of EPO production. The slow excretion of cisplatin from the kidney and increased retention after previous dosing would be consistent with delayed restoration of renal tubular function and delayed normalization of hematocrit and EPO levels.
The finding of protection from cisplatin-induced renal dysfunction and EPO deficiency in patients who smoked was unexpected. The mechanism for this is unknown, but several lines of thought are worth considering. The metabolism of many drugs is altered in smokers (49) , usually through altered hepatic metabolism; however, cisplatin does not undergo hepatic metabolism. Differences in cisplatin distribution have not been compared in smokers and nonsmokers. Thiol compounds can modulate cisplatin toxicity and serum thiocyanate levels are elevated in smokers. Whether thiocyanate can modulate cisplatin toxicity is not known. Elevated levels of heavy metals such as cadmium are found in cigarette smoke and the blood and renal tissue of smokers (50, 51). Cadmium is known to induce metallothionein synthesis. Metallothionein has been implicated in the sequestration of platinum and other metals and can prevent the lethal and renal toxicity caused by cisplatin administered to animals (52). It is not known whether metallothionein is elevated in smokers compared with nonsmokers or whether this might alter cisplatin renal toxicity in smokers. Studies along these lines would be of interest.
The lower renal toxicity and better EPO response seen in our cancer patients with complete remission of their tumor after chemotherapy was another unexplained finding. It is interesting that in vivo cisplatin resistance of tumors in animals has been associated with in vivo redistribution of the drug, with lower levels in the resistant tumor and higher levels in normal tissues (53) , which might explain this proactive inverse relation of host and tumor toxicity. In any event, these results in both humans and rats add to the case for the likelihood that cisplatininduced anemia is at least in part an iatrogenic endocrine deficiency syndrome.
